This clinical trial is focused on studying the effects of a medication called dapagliflozin, which is marketed under the name Forxiga, in patients undergoing hemodialysis. Hemodialysis is a treatment for people with severe kidney problems, such as Chronic Kidney Disease and Kidney Failure. The study also looks at patients with a heart condition known as Left Ventricular Hypertrophy, which is a thickening of the heart’s left pumping chamber. The purpose of the study is to compare the effects of dapagliflozin with a placebo on heart health in these patients.
Participants in the study will be randomly assigned to receive either dapagliflozin or a placebo. The study is designed to be double-blinded, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are not biased. The study will last for about six months, during which time the participants will continue their regular hemodialysis treatments while taking the study medication or placebo. The main focus will be on changes in the heart’s structure and function, particularly the Left Ventricular Mass, which is a measure of the heart’s size and health.
Throughout the study, various health markers will be monitored, including blood sugar levels, hormones, and heart function indicators. The goal is to see if dapagliflozin can improve heart health and overall quality of life for patients on hemodialysis. The study will provide valuable information on whether this medication can be beneficial for people with kidney and heart conditions who are undergoing hemodialysis.



Austria